NCT07391670 (IMFINZI-subQ) is a Phase 1 clinical trial of SC durvalumab + rHu in Solid Tumours, sponsored by AstraZeneca.

Who is sponsoring NCT07391670?

NCT07391670 is sponsored by AstraZeneca.

What drugs are being tested in NCT07391670?

Interventions in NCT07391670: SC durvalumab + rHu, IV durvalumab, Tremelimumab.

What condition does NCT07391670 study?

NCT07391670 studies Solid Tumours.

Is NCT07391670 still recruiting?

NCT07391670 is currently recruiting now. Last updated 17 April 2026.

Last reviewed 2026-04-17 · How we verify

NCT07391670: IMFINZI-subQ

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase I Dose Escalation and Dose Expansion Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Durvalumab

Recruiting now Phase 1 Last updated 17 April 2026

What this trial tests

Phase 1 trial testing SC durvalumab + rHu in Solid Tumours in 40 participants. Currently enrolling.

Timeline

31 March 2026

Primary endpoint
30 August 2027

30 August 2027

Quick facts

Lead sponsor	AstraZeneca
Phase	Phase 1
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	40
Start date	31 March 2026
Primary completion	30 August 2027
Estimated completion	30 August 2027
Sites	19 locations across Georgia, Taiwan, Poland, South Korea, Australia

Drugs / interventions tested

SC durvalumab + rHu — full drug profile →
IV durvalumab — full drug profile →
Tremelimumab (TREMELIMUMAB) — full drug profile →

Conditions studied

Solid Tumours — all drugs for Solid Tumours →

Sponsor

AstraZeneca — full company profile →

Who can join

18 and older, any sex, with Solid Tumours. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of the study is to determine a subcutaneous (SC: under the skin) durvalumab + recombinant human hyaluronidase (rHu) dose that yields systemic drug exposure similar to intravenous (IV: into the veins) durvalumab administration and to evaluate the pharmacokinetics and safety of SC durvalumab + rHu injection in participants with different types of solid tumours (cancers).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Solid Tumours

Currently open trials in the same condition.

NCT07446855 — Study of AZD4956 as Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced/Metastatic Homo · Phase 1, PHASE2 · recruiting
NCT07224425 — A Study in People With Advanced Cancer (Solid Tumours) to Test Different Doses of BI 3810944 and to Find Out Whether it · Phase 1 · recruiting
NCT07165067 — A Study of AP601 in Patients With Locally Unresectable Advanced or Metastatic Solid Tumors · Phase 1 · recruiting
NCT07403370 — Olanzapine Dose Comparison for the Prevention of HER-INV: A Network Meta-Analysis · recruiting
NCT07160725 — A Phase 1/2a, First-in-human, Study of BMS-986517 in Participants With Advanced Solid Tumors · Phase 1, PHASE2 · recruiting

Other AstraZeneca trials

Trials by the same sponsor.

NCT06998095 — Tezepelumab (Tezspire) Regulatory Postmarketing Surveillance in Korea · not yet recruiting
NCT07431775 — Saphnelo Use in Females of Child-bearing Potential · not yet recruiting
NCT07516184 — Explore the Diagnostic Value of Bronchodilation Test With Portable Oscillometry in Asthma Diagnosis · NA · not yet recruiting
NCT07279935 — Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resec · Phase 4 · not yet recruiting
NCT07279948 — A Single-arm Observational Study to Characterize the Demographic, Clinical Features and Outcomes of a Brazilian Cohort o · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07391670 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by AstraZeneca
Last refreshed: 17 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07391670.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing